Media headlines about CymaBay Therapeutics (NASDAQ:CBAY) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CymaBay Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.8189682975984 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Brokerages Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 Million (americanbankingnews.com)
- CymaBay Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CBAY-US : December 1, 2017 (finance.yahoo.com)
- CymaBay Therapeutics Inc to Post FY2019 Earnings of ($1.13) Per Share, Leerink Swann Forecasts (CBAY) (americanbankingnews.com)
- CymaBay Therapeutics (CBAY) Rating Reiterated by Leerink Swann (americanbankingnews.com)
- CymaBay Therapeutics (CBAY) Given “Buy” Rating at HC Wainwright (americanbankingnews.com)
CymaBay Therapeutics (CBAY) opened at $8.71 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.39 and a quick ratio of 7.39. CymaBay Therapeutics has a 1 year low of $1.46 and a 1 year high of $9.40.
A number of equities analysts recently weighed in on the stock. Leerink Swann reaffirmed a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, September 26th. SunTrust Banks assumed coverage on shares of CymaBay Therapeutics in a research report on Friday, August 18th. They set a “buy” rating and a $15.00 price objective for the company. Finally, Ifs Securities cut shares of CymaBay Therapeutics from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 11th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $14.50.
In other CymaBay Therapeutics news, Director Kurt Von Emster sold 211,124 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $8.09, for a total value of $1,707,993.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Carl Goldfischer sold 18,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $8.66, for a total transaction of $155,880.00. Following the completion of the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $77,940. The disclosure for this sale can be found here. Insiders sold a total of 447,257 shares of company stock valued at $3,730,862 in the last three months. 15.10% of the stock is currently owned by corporate insiders.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
What are top analysts saying about CymaBay Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CymaBay Therapeutics Inc and related companies.